GCGR

Synonyms

GL-R, GCGR, Glucagon Receptor, GGR, Receptors, Glucagon,

Description

Glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in the activation of adenylate cyclase and phospholipase C and in increased levels of the secondary messengers intracellular cAMP and calcium. In humans, the glucagon receptor is encoded by the GCGR gene.It plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.

KO Status

Immunization

Drug Information

Launched drugs: 22
Drugs in clinical trials: 5
Latest Research Phase:Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Glucagon (Xeris Pharmaceuticals)

Approved

Xeris Pharmaceuticals

Hypoglycemia

Glucagon (rDNA origin, Novo Nordisk)

GL-G

Approved

Novo Nordisk A/S

Hypoglycemia

SP-1373

SP-1373, VOD-107

Preclinical

Velocity Pharmaceutical Development

Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Obesity

Glucagon

MP-123456B

Approved

Eli Lilly And Company

Diabetes Mellitus, Type 2, Hypoglycemia, Diabetes Mellitus

Glucagon intranasal (Eli Lilly/Locemia Solutions)

AMG504-1, LY-900018

Approved

Amg Medical, Locemia Solutions

Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypoglycemia, Diabetes Mellitus

Glucagon (rDNA origin, Lilly)

Approved

Eli Lilly And Company

Diabetes Mellitus, Type 1, Hypoglycemia

Dasiglucagon

ZP-4207, ZP-GA-1

Phase 3 Clinical

Zealand Pharma A/S

Congenital Hyperinsulinism, Diabetes Mellitus, Type 1, Hypoglycemia, Hyperinsulinism

PRT-001

PRT-001

Phase 3 Clinical

Particle Therapeutics

Hypoglycemia

HM-15211

HM-15211

Phase 2 Clinical

Hanmi Pharmaceutical Co Ltd

Non-alcoholic Fatty Liver Disease, Obesity

Oxyntomodulin (Xenetic Biosciences)

Phase 2 Clinical

Pharmsynthez, Xenetic Biosciences

Diabetes Mellitus, Type 2, Obesity

volagidemab

AMG-477, REMD-477

Phase 2 Clinical

Amgen Inc

Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes Mellitus

LY-3305677

OXM-3, IBI-362, LY-3305677

Phase 2 Clinical

Eli Lilly And Company

Diabetes Mellitus, Type 2, Obesity

Pegapamodutide

TT-401, OPK-88003, LY-2944876, WG4ID2U7FT

Phase 2 Clinical

Eli Lilly And Company

Diabetes Mellitus, Type 2, Obesity

Efinopegdutide

JNJ-5111, HM-12525A, JNJ-64565111

Phase 2 Clinical

Hanmi Pharmaceutical Co Ltd

Diabetes Mellitus, Type 2, Obesity, Kidney Failure, Chronic

BI-456906

BI-456906

Phase 2 Clinical

Zealand Pharma A/S

Diabetes Mellitus, Type 2, Obesity

LGD-6972

LGD-6972, MB-11262, RVT-1502

Phase 2 Clinical

Ligand Pharmaceuticals Incorporated

Diabetes Mellitus, Type 2

Isosteviol

ISV, STX-03

Phase 2 Clinical

Stevia Pharma

Diabetes Mellitus, Type 2

Cotadutide

MEDI-0382

Phase 2 Clinical

Medimmune Llc

Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Renal Insufficiency, Obesity, Renal Insufficiency, Chronic

IONIS-GCGRRx

ISISGCGRRx, ISIS-449884, IONIS-GCGRRx

Phase 2 Clinical

Ionis

Diabetes Mellitus, Type 2

PRT-003

PRT-003

Phase 1 Clinical

Particle Therapeutics

What's Next for KO Library?

Please stay tuned for the latest progress of KO Library. We are open to co-development programs of antibody therapeutics using our RenMab™-target-knockout mice.
Please contact our team if you are interested in learning more about KO Library or partnering opportunities.